Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pamorelin
- Development stage
- Approved
- Lead developer
- Ipsen
- Modality
- Peptides
- Administration
- Intramuscular
01
Overview
Pamorelin is a sustained-release formulation of triptorelin embonate, a synthetic decapeptide agonist of the gonadotropin-releasing hormone (GnRH) receptor. It functions by initially stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by a period of receptor downregulation and desensitization. This results in a profound suppression of the pituitary-gonadal axis and a significant reduction in the production of sex steroids. In the context of clinical research led by Kenny Rodriguez-Wallberg (the ProFertil trial), Pamorelin is being evaluated in Phase 3 trials for its potential to protect ovarian function and preserve fertility in young women and teenagers undergoing gonadotoxic chemotherapy for various cancers, such as breast cancer, lymphoma, and leukemia. The induction of a temporary hypogonadotropic state is hypothesized to shield the ovaries from chemotherapy-induced damage, thereby preventing premature ovarian insufficiency.
- Brand names
- PamorelinTrelstarDecapeptylDipherelineGonapeptyl
- Other names
- Triptorelin embonateTriptorelin pamoate[D-Trp6]LHRH
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on Pamorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pamorelin.